Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010

Keizo Yamaguchi, Yoshikazu Ishii, Kazuhiro Tateda, Chikara Shimizu, Akira Suwabe, Mitsuo Kaku, Akira Hishinuma, Shigefumi Maesaki, Yoshio Kobayashi, Shigemi Kondo, Tetsuya Matsumoto, Morihiro Iwata, Sayoko Kawakami, Yoshihito Otsuka, Masato Maekawa, Tetsuya Yagi, Yuka Yamagishi, Shinichi Fujita, Yukio Hida, Kaname NakataniSatoshi Ichiyama, Ikuko Fujimoto, Hisashi Kohno, Hakuo Takahashi, Nobuchika Kusano, Yukinori Kurokawa, Yaeko Watanabe, Kiyoshi Negayama, Hitoshi Miyamoto, Makiko Kiyosuke, Kouichi Mashiba, Katsunori Yanagihara, Yosuke Aoki, Kazufumi Hiramatsu

Research output: Contribution to journalArticle

Abstract

Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin(TAZ/PIPC) in 4,080 bacterial strains isolated in 2010 were conducted in Japan. β-Lactamase production was investigated over 90% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group., about 60% of staphylococci and 11.1% of Haemophilus influenzae. An increase of the β-lactamase producers in H. influenzae strains was noted, when compared with previous investigations conducted between 2001 and 2006. Extended spectrum β-lactamase(ESBLs) producing strains in E. coli, K. pneumoniae and P. mirabilis were 17.8%, 3.9% and 12.8%, respectively. Increasing levels of ESBLs producers in E. coli, K. pneumoniae and P. mirabilis were investigated compared with previous investigations. Metallo β-lactamase producers in E. cloacae, P. aeruginosa and Acinetobacter spp. were 2.5%, 1.0% and 3.3%, respectively, and no strain of S. marcescens was detected. Susceptibility of 4,080 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute were distributed from 80.9% in P. aeruginosa to 100% in methicillin-susceptible S. aureus and coagulase-negative staphylococci, P. mirabilis, Proteus spp. (except for Proteus mirabilis) and H. influenzae including β-lactamase-negative ampicillin-resistant H. influenzae. When compared with those in previous investigations, susceptibility to TAZ/PIPC in this decade was not changed and some species of Enterobacteriaceae tend to be susceptible. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for the infectious diseases reported in various therapeutic guidelines.

Original languageEnglish
Pages (from-to)514-525
Number of pages12
JournalJapanese Journal of Chemotherapy
Volume61
Issue number6
Publication statusPublished - Nov 2013

Fingerprint

Haemophilus influenzae
Anti-Infective Agents
Klebsiella pneumoniae
Mirabilis
Pseudomonas aeruginosa
Enterobacter cloacae
Proteus mirabilis
Serratia marcescens
Acinetobacter
Escherichia coli
Staphylococcus
Citrobacter
Moraxella (Branhamella) catarrhalis
Bacteroides fragilis
Proteus
Methicillin
Coagulase
Enterobacteriaceae
Ampicillin
Communicable Diseases

Keywords

  • β-lactamase
  • Susceptibility
  • Tazobactam/piperacillin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Yamaguchi, K., Ishii, Y., Tateda, K., Shimizu, C., Suwabe, A., Kaku, M., ... Hiramatsu, K. (2013). Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010. Japanese Journal of Chemotherapy, 61(6), 514-525.

Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010. / Yamaguchi, Keizo; Ishii, Yoshikazu; Tateda, Kazuhiro; Shimizu, Chikara; Suwabe, Akira; Kaku, Mitsuo; Hishinuma, Akira; Maesaki, Shigefumi; Kobayashi, Yoshio; Kondo, Shigemi; Matsumoto, Tetsuya; Iwata, Morihiro; Kawakami, Sayoko; Otsuka, Yoshihito; Maekawa, Masato; Yagi, Tetsuya; Yamagishi, Yuka; Fujita, Shinichi; Hida, Yukio; Nakatani, Kaname; Ichiyama, Satoshi; Fujimoto, Ikuko; Kohno, Hisashi; Takahashi, Hakuo; Kusano, Nobuchika; Kurokawa, Yukinori; Watanabe, Yaeko; Negayama, Kiyoshi; Miyamoto, Hitoshi; Kiyosuke, Makiko; Mashiba, Kouichi; Yanagihara, Katsunori; Aoki, Yosuke; Hiramatsu, Kazufumi.

In: Japanese Journal of Chemotherapy, Vol. 61, No. 6, 11.2013, p. 514-525.

Research output: Contribution to journalArticle

Yamaguchi, K, Ishii, Y, Tateda, K, Shimizu, C, Suwabe, A, Kaku, M, Hishinuma, A, Maesaki, S, Kobayashi, Y, Kondo, S, Matsumoto, T, Iwata, M, Kawakami, S, Otsuka, Y, Maekawa, M, Yagi, T, Yamagishi, Y, Fujita, S, Hida, Y, Nakatani, K, Ichiyama, S, Fujimoto, I, Kohno, H, Takahashi, H, Kusano, N, Kurokawa, Y, Watanabe, Y, Negayama, K, Miyamoto, H, Kiyosuke, M, Mashiba, K, Yanagihara, K, Aoki, Y & Hiramatsu, K 2013, 'Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010', Japanese Journal of Chemotherapy, vol. 61, no. 6, pp. 514-525.
Yamaguchi, Keizo ; Ishii, Yoshikazu ; Tateda, Kazuhiro ; Shimizu, Chikara ; Suwabe, Akira ; Kaku, Mitsuo ; Hishinuma, Akira ; Maesaki, Shigefumi ; Kobayashi, Yoshio ; Kondo, Shigemi ; Matsumoto, Tetsuya ; Iwata, Morihiro ; Kawakami, Sayoko ; Otsuka, Yoshihito ; Maekawa, Masato ; Yagi, Tetsuya ; Yamagishi, Yuka ; Fujita, Shinichi ; Hida, Yukio ; Nakatani, Kaname ; Ichiyama, Satoshi ; Fujimoto, Ikuko ; Kohno, Hisashi ; Takahashi, Hakuo ; Kusano, Nobuchika ; Kurokawa, Yukinori ; Watanabe, Yaeko ; Negayama, Kiyoshi ; Miyamoto, Hitoshi ; Kiyosuke, Makiko ; Mashiba, Kouichi ; Yanagihara, Katsunori ; Aoki, Yosuke ; Hiramatsu, Kazufumi. / Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010. In: Japanese Journal of Chemotherapy. 2013 ; Vol. 61, No. 6. pp. 514-525.
@article{b8fab75d0c79460d8c17faafb7ced72e,
title = "Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010",
abstract = "Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin(TAZ/PIPC) in 4,080 bacterial strains isolated in 2010 were conducted in Japan. β-Lactamase production was investigated over 90{\%} of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group., about 60{\%} of staphylococci and 11.1{\%} of Haemophilus influenzae. An increase of the β-lactamase producers in H. influenzae strains was noted, when compared with previous investigations conducted between 2001 and 2006. Extended spectrum β-lactamase(ESBLs) producing strains in E. coli, K. pneumoniae and P. mirabilis were 17.8{\%}, 3.9{\%} and 12.8{\%}, respectively. Increasing levels of ESBLs producers in E. coli, K. pneumoniae and P. mirabilis were investigated compared with previous investigations. Metallo β-lactamase producers in E. cloacae, P. aeruginosa and Acinetobacter spp. were 2.5{\%}, 1.0{\%} and 3.3{\%}, respectively, and no strain of S. marcescens was detected. Susceptibility of 4,080 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute were distributed from 80.9{\%} in P. aeruginosa to 100{\%} in methicillin-susceptible S. aureus and coagulase-negative staphylococci, P. mirabilis, Proteus spp. (except for Proteus mirabilis) and H. influenzae including β-lactamase-negative ampicillin-resistant H. influenzae. When compared with those in previous investigations, susceptibility to TAZ/PIPC in this decade was not changed and some species of Enterobacteriaceae tend to be susceptible. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for the infectious diseases reported in various therapeutic guidelines.",
keywords = "β-lactamase, Susceptibility, Tazobactam/piperacillin",
author = "Keizo Yamaguchi and Yoshikazu Ishii and Kazuhiro Tateda and Chikara Shimizu and Akira Suwabe and Mitsuo Kaku and Akira Hishinuma and Shigefumi Maesaki and Yoshio Kobayashi and Shigemi Kondo and Tetsuya Matsumoto and Morihiro Iwata and Sayoko Kawakami and Yoshihito Otsuka and Masato Maekawa and Tetsuya Yagi and Yuka Yamagishi and Shinichi Fujita and Yukio Hida and Kaname Nakatani and Satoshi Ichiyama and Ikuko Fujimoto and Hisashi Kohno and Hakuo Takahashi and Nobuchika Kusano and Yukinori Kurokawa and Yaeko Watanabe and Kiyoshi Negayama and Hitoshi Miyamoto and Makiko Kiyosuke and Kouichi Mashiba and Katsunori Yanagihara and Yosuke Aoki and Kazufumi Hiramatsu",
year = "2013",
month = "11",
language = "English",
volume = "61",
pages = "514--525",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "6",

}

TY - JOUR

T1 - Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010

AU - Yamaguchi, Keizo

AU - Ishii, Yoshikazu

AU - Tateda, Kazuhiro

AU - Shimizu, Chikara

AU - Suwabe, Akira

AU - Kaku, Mitsuo

AU - Hishinuma, Akira

AU - Maesaki, Shigefumi

AU - Kobayashi, Yoshio

AU - Kondo, Shigemi

AU - Matsumoto, Tetsuya

AU - Iwata, Morihiro

AU - Kawakami, Sayoko

AU - Otsuka, Yoshihito

AU - Maekawa, Masato

AU - Yagi, Tetsuya

AU - Yamagishi, Yuka

AU - Fujita, Shinichi

AU - Hida, Yukio

AU - Nakatani, Kaname

AU - Ichiyama, Satoshi

AU - Fujimoto, Ikuko

AU - Kohno, Hisashi

AU - Takahashi, Hakuo

AU - Kusano, Nobuchika

AU - Kurokawa, Yukinori

AU - Watanabe, Yaeko

AU - Negayama, Kiyoshi

AU - Miyamoto, Hitoshi

AU - Kiyosuke, Makiko

AU - Mashiba, Kouichi

AU - Yanagihara, Katsunori

AU - Aoki, Yosuke

AU - Hiramatsu, Kazufumi

PY - 2013/11

Y1 - 2013/11

N2 - Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin(TAZ/PIPC) in 4,080 bacterial strains isolated in 2010 were conducted in Japan. β-Lactamase production was investigated over 90% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group., about 60% of staphylococci and 11.1% of Haemophilus influenzae. An increase of the β-lactamase producers in H. influenzae strains was noted, when compared with previous investigations conducted between 2001 and 2006. Extended spectrum β-lactamase(ESBLs) producing strains in E. coli, K. pneumoniae and P. mirabilis were 17.8%, 3.9% and 12.8%, respectively. Increasing levels of ESBLs producers in E. coli, K. pneumoniae and P. mirabilis were investigated compared with previous investigations. Metallo β-lactamase producers in E. cloacae, P. aeruginosa and Acinetobacter spp. were 2.5%, 1.0% and 3.3%, respectively, and no strain of S. marcescens was detected. Susceptibility of 4,080 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute were distributed from 80.9% in P. aeruginosa to 100% in methicillin-susceptible S. aureus and coagulase-negative staphylococci, P. mirabilis, Proteus spp. (except for Proteus mirabilis) and H. influenzae including β-lactamase-negative ampicillin-resistant H. influenzae. When compared with those in previous investigations, susceptibility to TAZ/PIPC in this decade was not changed and some species of Enterobacteriaceae tend to be susceptible. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for the infectious diseases reported in various therapeutic guidelines.

AB - Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin(TAZ/PIPC) in 4,080 bacterial strains isolated in 2010 were conducted in Japan. β-Lactamase production was investigated over 90% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group., about 60% of staphylococci and 11.1% of Haemophilus influenzae. An increase of the β-lactamase producers in H. influenzae strains was noted, when compared with previous investigations conducted between 2001 and 2006. Extended spectrum β-lactamase(ESBLs) producing strains in E. coli, K. pneumoniae and P. mirabilis were 17.8%, 3.9% and 12.8%, respectively. Increasing levels of ESBLs producers in E. coli, K. pneumoniae and P. mirabilis were investigated compared with previous investigations. Metallo β-lactamase producers in E. cloacae, P. aeruginosa and Acinetobacter spp. were 2.5%, 1.0% and 3.3%, respectively, and no strain of S. marcescens was detected. Susceptibility of 4,080 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute were distributed from 80.9% in P. aeruginosa to 100% in methicillin-susceptible S. aureus and coagulase-negative staphylococci, P. mirabilis, Proteus spp. (except for Proteus mirabilis) and H. influenzae including β-lactamase-negative ampicillin-resistant H. influenzae. When compared with those in previous investigations, susceptibility to TAZ/PIPC in this decade was not changed and some species of Enterobacteriaceae tend to be susceptible. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for the infectious diseases reported in various therapeutic guidelines.

KW - β-lactamase

KW - Susceptibility

KW - Tazobactam/piperacillin

UR - http://www.scopus.com/inward/record.url?scp=84890252760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890252760&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84890252760

VL - 61

SP - 514

EP - 525

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 6

ER -